ReviewNature reviews. Urology2012
A biomedical engineering approach to mitigate the errors of prostate biopsy.
Review in Nature reviews. Urology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Likelihood of sampling prostate cancer at systematic biopsy as a function of gland volume and number of cores.Prostate cancer and prostatic diseases · 2025Article
- Magnetic Resonance-Guided Prostate Ablation.Seminars in interventional radiology · 2019Review
- Multi-parametric MRI zone-specific diagnostic model performance compared with experienced radiologists for detection of prostate cancer.European radiology · 2019Article
- "Textural analysis of multiparametric MRI detects transition zone prostate cancer".European radiology · 2017Article
- MRI-Guided Prostate Biopsy of Native and Recurrent Prostate Cancer.Seminars in interventional radiology · 2016Review
- Targeted prostate biopsy and MR-guided therapy for prostate cancer.Abdominal radiology (New York) · 2016Review
- Targeted transperineal biopsy of the prostate has limited additional benefit over background cores for larger MRI-identified tumors.World journal of urology · 2016Article
- Detecting Prostate Cancer.Deutsches Arzteblatt international · 2015Article
- Zone-specific logistic regression models improve classification of prostate cancer on multi-parametric MRI.European radiology · 2015Article
- Logistic regression model for diagnosis of transition zone prostate cancer on multi-parametric MRI.European radiology · 2015Article
- Can we deliver randomized trials of focal therapy in prostate cancer?Nature reviews. Clinical oncology · 2014Review
- Prostate cancer tumour features on template prostate-mapping biopsies: implications for focal therapy.European urology · 2014Article
- Prostate cancer risk inflation as a consequence of image-targeted biopsy of the prostate: a computer simulation study.European urology · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
The current protocol for detecting and ruling out prostate cancer involves serum PSA testing followed by sampling of the prostate using a transrectal ultrasonography (TRUS)-guided biopsy. Many specialists have discussed how PSA screening has contributed to underdetection of clinically significant prostate cancer, overdiagnosis of clinically insignificant disease and poor risk stratification; however, little consideration has been given to the role of TRUS-guided biopsy in these errors. The performance of TRUS-guided biopsy is constrained by the biomechanical attributes of the sampling strategy, resulting in suboptimal detection efficiency of each core. By using a biomedical engineering approach, a uniform grid sampling strategy could be used to improve the detection efficiency of prostate biopsy. Moreover, the calibration of the sampling can be adjusted by altering the distance between needle deployments. Our model shows that for any given number of needle trajectories, a uniform grid approach will be superior to a divergent, nonuniform strategy for the detection of clinically important disease. This is an important message that should result in a move away from divergent sampling to a uniform grid approach for prostate biopsy.
Indexed as
Identifiers
22310216What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.